Answers are grounded in this paper and cite their sources.
Culture-negative infections and biofilm-associated disease challenge diagnostic methods that identify microbial material without preserving its location. We critically reviewed fluorescence in situ hybridization (FISH), peptide nucleic acid FISH (PNA-FISH), combined FISH and 16S rRNA-gene sequencing (FISHseq), and selected multiplex variants across clinical specimen matrices. This narrative review uses targeted literature searching and study-level evidence mapping; it does not claim systematic-review completeness or pooled diagnostic accuracy. Defined probes can expedite identification from growth-positive blood cultures, whereas direct FISH has limited value as a first-line test for microscopy-negative cerebrospinal fluid. In selected surgical heart-valve series, FISHseq increased reported organism identification relative to valve culture, although imperfect reference standards, selected populations and discrepancies in reported data limit interpretation. Vaginal, urinary, implant-associated and oral/intestinal studies show spatial insights but heterogeneous degrees of clinical validation. Results depend on probe design, biomass, processing, tissue matrix and panel coverage; an rRNA-FISH signal neither establishes viability nor proves etiologic causality. We propose Analytic Positivity → Etiologic Plausibility → Clinical Actionability (AP → EP → CA) as an interpretive aid that also accommodates polymicrobial communities and indeterminate findings. The framework is not externally clinically validated. FISH is best positioned as a matrix-specific adjunct, with predefined quality control, orthogonal testing and clinically meaningful implementation criteria rather than as a universal alternative to culture, nucleic-acid amplification or sequencing.
No takes yet. Share an insight, caveat, or question.
Сайфутдинова et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: